AparnaBio Introduces InVivoPlex™ - TUMOR Nanoparticle RNAi Delivery System
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Aparna Biosciences announced the introduction of InVivoPlex™ – TUMOR, the first tumor targeted nanoparticle reagent for in vivo translation of RNAi gene function research to mouse models of cancer.
This nanoparticle reagent system was presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR), in Washington, DC, April 17-21, 2010.
The capability of RNAi to selectively inhibit genes, recognized by a Nobel Prize, has led to explosive growth in understanding of tumor cell biology. To date RNAi based gene inhibition to identify potential new drug targets has largely involved in vitro experimentation. However, translation of this understanding into effective therapeutic strategies, validation of new targets for drug development, and highly selective therapeutics requires efficient in vivo delivery of RNAi agents in animal models. To address this need, AparnaBio has developed the InVivoPlex™ - TUMOR nanoparticle RNAi reagent.
It targets RNAi activity in vivo to tumors via their leaky blood vessels and importantly minimizes RNAi activity at organs where effects can be toxic or obscure effects at the tumor. InVivoPlex™ - TUMOR accelerates translation of research, an important stage in development of better treatments for cancer patients.
InVivoPlex™ - TUMOR nanoparticle reagents are for research use only, but are based on AparnaBio’s NanoElectroPlex™ clinically viable technology platform that is also being used to develop vaccines, therapeutics and imaging agents.
InVivoPlex™ –TUMOR development has been supported by funding from the National Institutes of Health and the State of Maryland, and funding for marketing and late stage product development by a Technology Growth Program grant from the Office of from Economic Development, Montgomery County, Maryland.
This nanoparticle reagent system was presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR), in Washington, DC, April 17-21, 2010.
The capability of RNAi to selectively inhibit genes, recognized by a Nobel Prize, has led to explosive growth in understanding of tumor cell biology. To date RNAi based gene inhibition to identify potential new drug targets has largely involved in vitro experimentation. However, translation of this understanding into effective therapeutic strategies, validation of new targets for drug development, and highly selective therapeutics requires efficient in vivo delivery of RNAi agents in animal models. To address this need, AparnaBio has developed the InVivoPlex™ - TUMOR nanoparticle RNAi reagent.
It targets RNAi activity in vivo to tumors via their leaky blood vessels and importantly minimizes RNAi activity at organs where effects can be toxic or obscure effects at the tumor. InVivoPlex™ - TUMOR accelerates translation of research, an important stage in development of better treatments for cancer patients.
InVivoPlex™ - TUMOR nanoparticle reagents are for research use only, but are based on AparnaBio’s NanoElectroPlex™ clinically viable technology platform that is also being used to develop vaccines, therapeutics and imaging agents.
InVivoPlex™ –TUMOR development has been supported by funding from the National Institutes of Health and the State of Maryland, and funding for marketing and late stage product development by a Technology Growth Program grant from the Office of from Economic Development, Montgomery County, Maryland.
